{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:28:09Z","timestamp":1788672489092,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our objective was to investigate trends in the treatment of patients with late-onset rheumatoid arthritis (LORA) using data from the National Database of Rheumatic Diseases in Japan (NinJa).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients registered in the National Database of Rheumatic Diseases in Japan were classified according to the disease onset: at &amp;lt;65\u2009years (young-onset rheumatoid arthritis); at 65\u201374\u2009years (early LORA); and at \u226575\u2009years (late LORA). Chronological changes in the treatment and disease activity were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 7178, 13,171, 15,295, and 15,943 patients were evaluated in 2010, 2013, 2016, and 2019, respectively. In all groups, the use of methotrexate gradually decreased, whereas that of biological\/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) increased; the use of tumor necrosis factor inhibitors decreased, whereas that of non-tumor necrosis factor inhibitors increased. LORA was characterized by more single DMARD use and less methotrexate and biological\/targeted synthetic DMARD use. Tumor necrosis factor inhibitors and interleukin-6 inhibitors were used less frequently, whereas abatacept was utilized more frequently in late versus early LORA. Conventional synthetic DMARD (excluding methotrexate) and glucocorticoid use was higher in late versus early LORA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis revealed chronological changes in the treatment of LORA in Japan. Differences between early and late LORA suggest that patients are not a homogeneous population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roae006","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T08:18:16Z","timestamp":1705479496000},"page":"881-891","source":"Crossref","is-referenced-by-count":17,"title":["Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: Data from the NinJa study"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-3211","authenticated-orcid":false,"given":"Toshihiro","family":"Matsui","sequence":"first","affiliation":[{"name":"Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Fukuoka National Hospital , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-4010","authenticated-orcid":false,"given":"Tetsuji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Medical University Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Tokyo National Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"2024101507120154500_R1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2024101507120154500_R2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2024101507120154500_R3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/acr.21900","article-title":"Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration","volume":"65","author":"Eriksson","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2024101507120154500_R4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00296-014-2974-6","article-title":"Prevalence and incidence of rheumatoid arthritis in Italy","volume":"34","author":"Rossini","year":"2014","journal-title":"Rheumatol Int"},{"key":"2024101507120154500_R5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00296-017-3925-9","article-title":"Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization","volume":"38","author":"Won","year":"2018","journal-title":"Rheumatol Int"},{"key":"2024101507120154500_R6","article-title":"Prevalence trend and disparities in rheumatoid arthritis among US adults, 2005\u20132018","volume":"10","author":"Xu","year":"2021","journal-title":"J Clin Med Res"},{"key":"2024101507120154500_R7","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s10067-017-3796-1","article-title":"Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study","volume":"36","author":"Jean","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2024101507120154500_R8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/art.1780280905","article-title":"The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration","volume":"28","author":"Deal","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2024101507120154500_R9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0049-0172(94)90087-6","article-title":"Elderly-onset rheumatoid arthritis","volume":"23","author":"van Schaardenburg","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"2024101507120154500_R10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X17740075","article-title":"An autumn tale: geriatric rheumatoid arthritis","volume":"10","author":"Kobak","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024101507120154500_R11","first-page":"1285","article-title":"Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis","volume":"18","author":"van der Heijde","year":"1991","journal-title":"J Rheumatol"},{"key":"2024101507120154500_R12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/keh143","article-title":"Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica","volume":"43","author":"Lopez-Hoyos","year":"2004","journal-title":"Rheumatology"},{"key":"2024101507120154500_R13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbspin.2010.04.004","article-title":"Elderly-onset rheumatoid arthritis","volume":"77","author":"Soubrier","year":"2010","journal-title":"Joint Bone Spine"},{"key":"2024101507120154500_R14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0889-857X(05)70154-X","article-title":"Elderly-onset rheumatoid arthritis","volume":"26","author":"Yazici SAP","year":"2000","journal-title":"Rheum Dis Clin North Am"},{"key":"2024101507120154500_R15","doi-asserted-by":"crossref","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study","volume":"16","author":"Innala","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2024101507120154500_R16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/1756-185X.12861","article-title":"Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort","volume":"20","author":"Tan","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2024101507120154500_R17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/ket449","article-title":"Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort","volume":"53","author":"Arnold","year":"2014","journal-title":"Rheumatology"},{"key":"2024101507120154500_R18","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","article-title":"Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?","volume":"65","author":"Tutuncu","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024101507120154500_R19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology"},{"key":"2024101507120154500_R20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10067-015-3031-x","article-title":"The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative","volume":"35","author":"Ruban","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2024101507120154500_R21","article-title":"Systemic inflammatory parameters in patients with elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) \u2013 an observational study","volume":"10","author":"Targo\u0144ska-St\u0119pniak","year":"2021","journal-title":"J Clin Med Res"},{"key":"2024101507120154500_R22","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1093\/rheumatology\/keaa922","article-title":"Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study","volume":"60","author":"Sugihara","year":"2021","journal-title":"Rheumatology"},{"key":"2024101507120154500_R23","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3899\/jrheum.201135","article-title":"Similarity of response to biologics between elderly-onset rheumatoid arthritis (EORA) and non-EORA elderly patients: from the FIRST registry","volume":"48","author":"Ochi","year":"2021","journal-title":"J Rheumatol"},{"key":"2024101507120154500_R24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024101507120154500_R25","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024101507120154500_R26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024101507120154500_R27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/mr\/roab013","article-title":"Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?","volume":"32","author":"Uchiyama","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024101507120154500_R28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rdc.2006.12.006","article-title":"Rheumatic disease in the elderly: rheumatoid arthritis","volume":"33","author":"Tutuncu","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"2024101507120154500_R29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024101507120154500_R30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/ard.2006.063834","article-title":"Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan","volume":"66","author":"Matsui","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024101507120154500_R31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/eci.12.35","article-title":"Current treatments of rheumatoid arthritis: from the \u201cNinJa\u201d registry","volume":"8","author":"Saeki","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"2024101507120154500_R32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2024101507120154500_R33","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024101507120154500_R34","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024101507120154500_R35","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis Rheum"},{"key":"2024101507120154500_R36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","article-title":"Therapeutic criteria in rheumatoid arthritis","volume":"140","author":"Steinbrocker","year":"1949","journal-title":"J Am Med Assoc"},{"key":"2024101507120154500_R37","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02952-1","article-title":"Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative","volume":"24","author":"Li","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2024101507120154500_R38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/14397595.2021.1883251","article-title":"Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity","volume":"31","author":"Kumagai","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2024101507120154500_R39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024101507120154500_R40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000164393","article-title":"Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease","volume":"55","author":"Chen","year":"2009","journal-title":"Gerontology"},{"key":"2024101507120154500_R41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024101507120154500_R42","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis","volume":"353","author":"Hazlewood","year":"2016","journal-title":"BMJ"},{"key":"2024101507120154500_R43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2024101507120154500_R44","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2169\/internalmedicine.2226-18","article-title":"Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis","volume":"58","author":"Kurata","year":"2019","journal-title":"Intern Med"},{"key":"2024101507120154500_R45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0300060516686872","article-title":"An assessment of the current treatment landscape for rheumatology patients in Qatar: recognising unmet needs and moving towards solutions","volume":"45","author":"Emadi","year":"2017","journal-title":"J Int Med Res"},{"key":"2024101507120154500_R46","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40744-023-00561-1","article-title":"Association of hydroxychloroquine use with a dose-dependent decrease in mortality risk in patients with elderly-onset rheumatoid arthritis","volume":"10","author":"Lin","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024101507120154500_R47","article-title":"Sulfasalazine for rheumatoid arthritis","volume":"1998","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101507120154500_R48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae006\/56551995\/roae006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/881\/59755369\/roae006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/881\/59755369\/roae006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T03:12:52Z","timestamp":1728961972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/5\/881\/7584939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,22]]},"published-print":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae006","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,1,22]]}}}